Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL double-deficient mice

Blood

Volumn 115, Issue 16, 2010, Pages 3258-3268

  Sedger, Lisa M ^a,b   Katewa, Arna ^a,b   Pettersen, Ann K ^a   Osvath, Sarah R ^b   Farrell, Geoff C ^b   Stewart, Graeme J ^b   Bendall, Linda J ^c   Alexander, Stephen I ^d  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD45 ANTIGEN; DNA ANTIBODY; FAS LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RHEUMATOID FACTOR; THROMBOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; B LYMPHOCYTE; BLEEDING; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; HOMEOSTASIS; IMMUNOSTIMULATION; LYMPH FOLLICLE; LYMPHOCYTE ACTIVATION; LYMPHOCYTOSIS; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77951476070     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-255497     Document Type: Article

References (50)

1. Strasser A. Apoptosis signalling. Annu Rev Biochem. 2000;69:217-245.
2. Aggarwal BB, Shishodia S, Ashikawa K, Bharti AC. The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Curr Drug Targets Inflamm Allergy. 2002;1:(4)327-341.
3. Ruby J, Bluethmann H, Peschon JJ. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J Exp Med. 1997;186(9):1591-1596. (Pubitemid 27479819)
4. Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet. 1995;11(3):294-300.
5. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterisation of a new member of the TNF family that induces apoptosis. Immunity. 1995;3(6):673-682. (Pubitemid 26091143)
6. Sedger LM, Shows DM, Blanton RA, et al. IFN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol. 1999;163:(2)920-926.
7. Sedger LM, Glaccum M, Schuh JC, et al. Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol. 2002;32(8):2246-2254. (Pubitemid 34965887)
8. Smyth MJ, Cretney E, Takeda K, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med. 2001;193(6):661-670. (Pubitemid 32524460)
9. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med. 2001;7(1):94-100. (Pubitemid 32095647)
10. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med. 2002;195:(2)161-169. (Pubitemid 34461260)
11. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5(2):157-163. (Pubitemid 29068521)
12. Fingleton B, Carter KJ, Matrisian LM. Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model. Cancer Res. 2007;67(10):4800-4806. (Pubitemid 46910188)
13. Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH. Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis. 2003;8(2):151-160.
14. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med. 1999;189(8):1343-1354.
15. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002;21(17):4520-4530. (Pubitemid 34984339)
16. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76(6):969-976. (Pubitemid 24106378)
17. Hu M, Watson D, Zhang GY, et al. Long-term cardiac allograft survival across an MHC mismatch after "pruning" of alloreactive CD4 T cells. J Immunol. 2008;180(10):6593-6603.
18. Körner H, Cretney E, Wilhelm P, et al. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J Exp Med. 2000;191(1):89-96. (Pubitemid 30043650)
19. Wiede F, Vana K, Sedger LM, Lechner A, Körner H. TNF-dependent overexpression of CCL21 is an underlying cause of progressive lymphoaccumulation in generalized lymphoproliferative disorder. Eur J Immunol. 2007;37(2):351-357. (Pubitemid 46915574)
20. Kovalenko A, Kim JC, Kang TB, et al. Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. J Exp Med. 2009;206(10):2161-2177.
21. Kayagaki N, Yamaguchi N, Abe M, et al. Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL). Cell Immunol. 2002;219(2):82-91. (Pubitemid 36259612)
22. Ahmad R, Menezes J, Knafo L, Ahmad A. Activated human platelets express Fas-L and induce apoptosis in Fas-positive tumor cells. J Leukoc Biol. 2001;69(1):123-128. (Pubitemid 32095126)
23. Crist SA, Elzey BD, Ludwig AT, et al. Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. Exp Hematol. 2004;32(11):1073-1081.
24. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511-6521.
25. Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost. 2009;7(2):322-329.
26. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356(6367):314-317.
27. Adachi M, Suematsu S, Suda T, et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci U S A. 1996;93(5):2131-2136. (Pubitemid 26079893)
28. Woelfel M, Bixby J, Brehm MA, Chan FK. Transgenic expression of the viral FLIP MC159 causes lpr/gld-like lymphoproliferation and autoimmunity. J Immunol. 2006;177(6):3814-3820. (Pubitemid 44359915)
29. Hughes PD, Belz GT, Fortner KA, Budd RC, Strasser A, Bouillet P. Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity. 2008;28(2):197-205. (Pubitemid 351215234)
30. Hutcheson J, Scatizzi JC, Siddiqui AM, et al. Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity. 2008;28(2):206-217. (Pubitemid 351215233)
31. + T cell contraction. Immunity. 2008;28(2):218-230.
32. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impairs apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81(6):935-946.
33. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419(6905):395-399.
34. Wang J, Zheng L, Lobito A, et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999;98(1):47-58. (Pubitemid 29331195)
35. Dechant MJ, Scheuerpflug CG, Pauly E, van der Werff Ten Bosch J, Debatin KM, Fellenberg J. Screening, identification, and functional analysis of three novel missense mutations in the TRADD gene in children with ALL and ALPS. Pediatr Blood Cancer. 2008;51(5):616-620.
36. Renno T, Attinger A, Rimoldi D, Hahne M, Tschopp J, MacDonald HR. Expression of B220 on activated T cell blasts precedes apoptosis. Eur J Immunol. 1998;28(2):540-547. (Pubitemid 28101731)
37. Fuchs H, Posovszky C, Lahr G, van der Werff ten Bosch J, Boehler T, Debatin KM. Residual CD95-pathway function in children with autoimmune lymphoproliferative syndrome is independent from clinical state and genotype of CD95 mutation. Pediatr Res. 2009;65(2):163-168.
38. Zheng L, Fisher G, Miller RE, Peschon J, Lynch J, Lenardo M. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;3773:348-351.
39. Diehl GE, Yue HH, Hsieh K, et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity. 2004;21(6):877-889. (Pubitemid 39626676)
40. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005;434(7029):88-93.
41. Pellegrini M, Belz G, Bouillet P, Strasser A. Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein Bim. Proc Natl Acad Sci U S A. 2003;100(24):14175-14180. (Pubitemid 37499210)
42. + T cells. J Immunol. 2008;181(1):440-448.
43. Marlies A, Udo G, Juergen B, Bernd S, Herrmann M, Haas JP. The expanded double negative T cell populations of a patient with ALPS are not clonally related to CD4+ or to CD8+ T cells. Autoimmunity. 2007;40(4):299-301. (Pubitemid 46845525)
44. Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001;98(1):194-2000.
45. Bouillet P, Purton JF, Godfrey DI, et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature. 2002;415(6874):922-926. (Pubitemid 34174755)
46. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. J Clin Invest. 1998;102(7):1393-1402.
47. Rao VK, Price S, Perkins K, et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009;52(7):847-852.
48. Song K, Chen Y, Goke R, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med. 2000;191(7):1095-1104.
49. Lamhamedi-Cherradi SE, Zheng S, Tisch RM, Chen YH. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes. 2003;52(9):2274-2278. (Pubitemid 37059497)
50. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol. 2001;166(2):1314-1319. (Pubitemid 32060293)